Global Antiviral Drug Packaging 麻豆原创 Research Report 2025

Publication ID:

PB504252690

Publication Date:

April 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Packaging [2]

Industry & Manufacturing [3]

Description:

The global market for Antiviral Drug Packaging was valued at US$ 28320 million in the year 2024 and is projected to reach a revised size of US$ 36460 million by 2031, growing at a CAGR of 3.7% during the forecast period.
Antiviral drug packaging is specially designed for packaging antiviral drugs. Antiviral drugs are a class of medication used specifically for treating viral infections such as influenza, herpes virus infections, viral hepatitis and human immunodeficiency virus.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antiviral Drug Packaging, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antiviral Drug Packaging.
The Antiviral Drug Packaging market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antiviral Drug Packaging market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antiviral Drug Packaging manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Avery Dennison Corporation
E.I. du Pont de Nemours
CCL Industries Inc
BioCote
Avient
Mondi
Biomaster
BASF
Lonza
Takex Labo Co. Ltd
Berry
Lageen Tubes.
Segment by Type
Rigid Plastic
Flexible Blister Foils
Others
Segment by Application
Pharmaceuticals
Healthcare
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antiviral Drug Packaging manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antiviral Drug Packaging in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Antiviral Drug Packaging 麻豆原创 Overview
1.1 Product Definition
1.2 Antiviral Drug Packaging by Type
1.2.1 Global Antiviral Drug Packaging 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Rigid Plastic
1.2.3 Flexible Blister Foils
1.2.4 Others
1.3 Antiviral Drug Packaging by Application
1.3.1 Global Antiviral Drug Packaging 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Pharmaceuticals
1.3.3 Healthcare
1.4 Global Antiviral Drug Packaging 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Antiviral Drug Packaging Revenue 2020-2031
1.4.2 Global Antiviral Drug Packaging Sales 2020-2031
1.4.3 Global Antiviral Drug Packaging 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Antiviral Drug Packaging 麻豆原创 Competition by Manufacturers
2.1 Global Antiviral Drug Packaging Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Antiviral Drug Packaging Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Antiviral Drug Packaging Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Antiviral Drug Packaging, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antiviral Drug Packaging, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antiviral Drug Packaging, Product Type & Application
2.7 Global Key Manufacturers of Antiviral Drug Packaging, Date of Enter into This Industry
2.8 Global Antiviral Drug Packaging 麻豆原创 Competitive Situation and Trends
2.8.1 Global Antiviral Drug Packaging 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Antiviral Drug Packaging Players 麻豆原创 Share by Revenue
2.8.3 Global Antiviral Drug Packaging 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiviral Drug Packaging 麻豆原创 Scenario by Region
3.1 Global Antiviral Drug Packaging 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Antiviral Drug Packaging Sales by Region: 2020-2031
3.2.1 Global Antiviral Drug Packaging Sales by Region: 2020-2025
3.2.2 Global Antiviral Drug Packaging Sales by Region: 2026-2031
3.3 Global Antiviral Drug Packaging Revenue by Region: 2020-2031
3.3.1 Global Antiviral Drug Packaging Revenue by Region: 2020-2025
3.3.2 Global Antiviral Drug Packaging Revenue by Region: 2026-2031
3.4 North America Antiviral Drug Packaging 麻豆原创 Facts & Figures by Country
3.4.1 North America Antiviral Drug Packaging 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Antiviral Drug Packaging Sales by Country (2020-2031)
3.4.3 North America Antiviral Drug Packaging Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiviral Drug Packaging 麻豆原创 Facts & Figures by Country
3.5.1 Europe Antiviral Drug Packaging 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Antiviral Drug Packaging Sales by Country (2020-2031)
3.5.3 Europe Antiviral Drug Packaging Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiviral Drug Packaging 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Antiviral Drug Packaging 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Antiviral Drug Packaging Sales by Region (2020-2031)
3.6.3 Asia Pacific Antiviral Drug Packaging Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiviral Drug Packaging 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Antiviral Drug Packaging 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Antiviral Drug Packaging Sales by Country (2020-2031)
3.7.3 Latin America Antiviral Drug Packaging Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antiviral Drug Packaging 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Antiviral Drug Packaging 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Antiviral Drug Packaging Sales by Country (2020-2031)
3.8.3 Middle East and Africa Antiviral Drug Packaging Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiviral Drug Packaging Sales by Type (2020-2031)
4.1.1 Global Antiviral Drug Packaging Sales by Type (2020-2025)
4.1.2 Global Antiviral Drug Packaging Sales by Type (2026-2031)
4.1.3 Global Antiviral Drug Packaging Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Antiviral Drug Packaging Revenue by Type (2020-2031)
4.2.1 Global Antiviral Drug Packaging Revenue by Type (2020-2025)
4.2.2 Global Antiviral Drug Packaging Revenue by Type (2026-2031)
4.2.3 Global Antiviral Drug Packaging Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Antiviral Drug Packaging Price by Type (2020-2031)
5 Segment by Application
5.1 Global Antiviral Drug Packaging Sales by Application (2020-2031)
5.1.1 Global Antiviral Drug Packaging Sales by Application (2020-2025)
5.1.2 Global Antiviral Drug Packaging Sales by Application (2026-2031)
5.1.3 Global Antiviral Drug Packaging Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Antiviral Drug Packaging Revenue by Application (2020-2031)
5.2.1 Global Antiviral Drug Packaging Revenue by Application (2020-2025)
5.2.2 Global Antiviral Drug Packaging Revenue by Application (2026-2031)
5.2.3 Global Antiviral Drug Packaging Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Antiviral Drug Packaging Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Avery Dennison Corporation
6.1.1 Avery Dennison Corporation Company Information
6.1.2 Avery Dennison Corporation Description and Business Overview
6.1.3 Avery Dennison Corporation Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Avery Dennison Corporation Antiviral Drug Packaging Product Portfolio
6.1.5 Avery Dennison Corporation Recent Developments/Updates
6.2 E.I. du Pont de Nemours
6.2.1 E.I. du Pont de Nemours Company Information
6.2.2 E.I. du Pont de Nemours Description and Business Overview
6.2.3 E.I. du Pont de Nemours Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.2.4 E.I. du Pont de Nemours Antiviral Drug Packaging Product Portfolio
6.2.5 E.I. du Pont de Nemours Recent Developments/Updates
6.3 CCL Industries Inc
6.3.1 CCL Industries Inc Company Information
6.3.2 CCL Industries Inc Description and Business Overview
6.3.3 CCL Industries Inc Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CCL Industries Inc Antiviral Drug Packaging Product Portfolio
6.3.5 CCL Industries Inc Recent Developments/Updates
6.4 BioCote
6.4.1 BioCote Company Information
6.4.2 BioCote Description and Business Overview
6.4.3 BioCote Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.4.4 BioCote Antiviral Drug Packaging Product Portfolio
6.4.5 BioCote Recent Developments/Updates
6.5 Avient
6.5.1 Avient Company Information
6.5.2 Avient Description and Business Overview
6.5.3 Avient Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Avient Antiviral Drug Packaging Product Portfolio
6.5.5 Avient Recent Developments/Updates
6.6 Mondi
6.6.1 Mondi Company Information
6.6.2 Mondi Description and Business Overview
6.6.3 Mondi Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Mondi Antiviral Drug Packaging Product Portfolio
6.6.5 Mondi Recent Developments/Updates
6.7 Biomaster
6.7.1 Biomaster Company Information
6.7.2 Biomaster Description and Business Overview
6.7.3 Biomaster Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Biomaster Antiviral Drug Packaging Product Portfolio
6.7.5 Biomaster Recent Developments/Updates
6.8 BASF
6.8.1 BASF Company Information
6.8.2 BASF Description and Business Overview
6.8.3 BASF Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.8.4 BASF Antiviral Drug Packaging Product Portfolio
6.8.5 BASF Recent Developments/Updates
6.9 Lonza
6.9.1 Lonza Company Information
6.9.2 Lonza Description and Business Overview
6.9.3 Lonza Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Lonza Antiviral Drug Packaging Product Portfolio
6.9.5 Lonza Recent Developments/Updates
6.10 Takex Labo Co. Ltd
6.10.1 Takex Labo Co. Ltd Company Information
6.10.2 Takex Labo Co. Ltd Description and Business Overview
6.10.3 Takex Labo Co. Ltd Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Takex Labo Co. Ltd Antiviral Drug Packaging Product Portfolio
6.10.5 Takex Labo Co. Ltd Recent Developments/Updates
6.11 Berry
6.11.1 Berry Company Information
6.11.2 Berry Description and Business Overview
6.11.3 Berry Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Berry Antiviral Drug Packaging Product Portfolio
6.11.5 Berry Recent Developments/Updates
6.12 Lageen Tubes.
6.12.1 Lageen Tubes. Company Information
6.12.2 Lageen Tubes. Description and Business Overview
6.12.3 Lageen Tubes. Antiviral Drug Packaging Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Lageen Tubes. Antiviral Drug Packaging Product Portfolio
6.12.5 Lageen Tubes. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiviral Drug Packaging Industry Chain Analysis
7.2 Antiviral Drug Packaging Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiviral Drug Packaging Production Mode & Process Analysis
7.4 Antiviral Drug Packaging Sales and 麻豆原创ing
7.4.1 Antiviral Drug Packaging Sales Channels
7.4.2 Antiviral Drug Packaging Distributors
7.5 Antiviral Drug Packaging Customer Analysis
8 Antiviral Drug Packaging 麻豆原创 Dynamics
8.1 Antiviral Drug Packaging Industry Trends
8.2 Antiviral Drug Packaging 麻豆原创 Drivers
8.3 Antiviral Drug Packaging 麻豆原创 Challenges
8.4 Antiviral Drug Packaging 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Avery Dennison Corporation
E.I. du Pont de Nemours
CCL Industries Inc
BioCote
Avient
Mondi
Biomaster
BASF
Lonza
Takex Labo Co. Ltd
Berry
Lageen Tubes.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.